Pure and Cure Healthcare Private Limited, a wholly-owned subsidiary of akums drugs & pharma , has acquired the manufacturing business of Oriflame India Private Limited for a total consideration of ₹56 crore. The Board of Directors approved the transaction on July 23, 2026, marking Akums' strategic entry into the color cosmetics segment while expanding its capabilities in skincare and wellness products for both Indian and global markets.

The acquisition includes two manufacturing facilities located in Roorkee, Uttarakhand, and Noida, Uttar Pradesh, along with a leased warehouse in Noida. Notably, the trademark and marketing rights for Oriflame’s products in India are excluded from this transaction. The move aims to leverage existing manufacturing capacity to diversify Akums' product portfolio beyond its core pharmaceutical operations.

Transaction Details

The deal is structured as a cash consideration purchase and is not classified as a related-party transaction. No promoter or group company holds an interest in the acquired business, ensuring the transaction was conducted at arm's length. The company confirmed that no prior governmental or regulatory approvals are required for this acquisition.

Strategic Implications

This acquisition represents a significant diversification step for Akums Drugs & Pharmaceuticals Limited. By acquiring established manufacturing infrastructure, the company can rapidly scale its presence in the fast-growing Indian cosmetics market without the lead time associated with greenfield projects. The inclusion of facilities in both Uttarakhand and Uttar Pradesh provides geographic diversification in production capabilities.

The exclusion of marketing and trademark rights suggests Akums intends to utilize these manufacturing assets for its own brands or contract manufacturing, rather than continuing the Oriflame brand portfolio. This approach allows the company to focus on operational efficiency and product development within the cosmetics and wellness space.

Regulatory Disclosures

The intimation was filed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The disclosure was submitted to the National Stock Exchange of India Ltd and BSE Limited on July 23, 2026, at 5:56 PM IST. Dharamvir Malik, Company Secretary & Compliance Officer, signed the filing.

Akums Drugs & Pharmaceuticals announced the voting results for its 22nd Annual General Meeting held on July 10, 2026, confirming the approval of all six resolutions. Shareholders sanctioned the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and declared a dividend on equity shares for the same period. The meeting, conducted via video conferencing, was attended by 123 members, with 71,018 shareholders recorded as of the cut-off date of July 3, 2026.

Voting Outcomes

The resolutions were passed with the requisite majority, though special resolutions regarding remuneration revisions faced significant opposition. The re-appointment of Mr. Sanjay Sinha (DIN: 03627342) as Director was approved with 98.92% of votes in favour. However, the special resolutions to revise the remuneration of Managing Directors Mr. Sanjeev Jain and Mr. Sandeep Jain received 91.58% approval, with 8.42% of votes cast against them.

Scrutinizer's Report

CS Suresh Pandey of SPG and Associates, appointed as the Scrutinizer, oversaw the remote e-voting process conducted in collaboration with National Securities Depository Limited (NSDL). Remote e-voting commenced on July 6, 2026, and concluded on July 9, 2026. The votes were unblocked on July 10, 2026, in the presence of independent witnesses. The results have been communicated to the National Stock Exchange of India Ltd. and BSE Limited.